Clover Health Investments, Corp. reported its third quarter 2024 financial results on November 6, 2024. The company delivered 9% total revenue growth year-to-date compared to the prior year period, demonstrating strong top-line performance.
GAAP Net Loss from Continuing Operations improved by $117.4 million year-over-year year-to-date, while Adjusted EBITDA improved by $87.2 million year-over-year year-to-date. These improvements highlight the effectiveness of Clover's technology-first physician empowerment model and care management strategies.
The company increased its full-year 2024 Adjusted EBITDA guidance midpoint to a range of $55 million - $65 million. This updated guidance positions Clover Health to invest in membership growth opportunities for 2025 while maintaining strong profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.